The manufacturer of Izervay is Ipsen Biopharmaceuticals [1]. Ipsen is a global specialty-driven biopharmaceutical group focused on innovative medicines in oncology, neuroscience, and rare diseases [1].
What is Izervay used for?
Izervay is a medication used for the treatment of adult patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) [2][3]. It is indicated for patients who have received at least one prior systemic therapy [2][3].
How does Izervay work?
Izervay is a KRAS G12C inhibitor [2][3]. It works by specifically targeting and inhibiting the KRAS G12C protein, which is a mutated form of a protein commonly found in certain types of non-small cell lung cancer [2][3]. By blocking this mutated protein, Izervay can help to slow or stop the growth of cancer cells [2][3].
What is the clinical data supporting Izervay?
The efficacy of Izervay was established in the CodeBreaK 100 study, a phase 2 trial [2][3]. In this trial, patients with KRAS G12C-mutated NSCLC who had previously been treated with at least one systemic therapy received Izervay [2][3]. The study demonstrated a significant objective response rate (ORR) and duration of response (DoR) in this patient population [2][3].
When does Izervay's patent expire?
Information on specific patent expiry dates for Izervay would be available through specialized patent tracking services. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods [4].
What are the potential side effects of Izervay?
Common side effects associated with Izervay include diarrhea, nausea, vomiting, fatigue, and anemia [2][3]. More serious side effects can occur and may require medical attention [2][3]. Patients should discuss potential risks and side effects with their healthcare provider [2][3].
Are there other KRAS G12C inhibitors available?
Yes, other KRAS G12C inhibitors are available or in development for the treatment of KRAS G12C-mutated cancers. These include drugs like sotorasib, which also targets the KRAS G12C mutation [5]. The landscape of targeted therapies for KRAS-mutated cancers is evolving, with ongoing research into new agents and combination strategies [5].
What is the regulatory status of Izervay?
Izervay has received regulatory approvals in various regions, including the United States by the Food and Drug Administration (FDA) and in Europe by the European Medicines Agency (EMA), for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior therapy [2][3].
What does KRAS G12C mutation mean for lung cancer patients?
The KRAS G12C mutation is a specific genetic alteration found in a subset of non-small cell lung cancer (NSCLC) patients, typically around 13% of NSCLC cases with a KRAS mutation [2][3]. Identifying this mutation is important because it can guide treatment decisions, allowing for the use of targeted therapies like Izervay [2][3].
Sources:
[1] https://www.ipsen.com/
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-izervay-sotorasib-patients-previously-treated-advanced-non-small-cell-lung-cancer
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/izervay
[4] https://drugpatentwatch.com/
[5] https://www.cancer.gov/about-cancer/treatment/research/kras-targeted-therapies